Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Comfort Systems USA Inc (FIX) vs Sana Biotechnology Inc (SANA) Price & Performance

Comfort Systems USA IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Comfort Systems USA Inc vs Sana Biotechnology Inc — how do they compare? Comfort Systems USA Inc trades at $1,664.97 (market cap $61.14B), while Sana Biotechnology Inc trades at $3.23 (market cap $987.94M). The key difference: Comfort Systems USA Inc is far larger — about 61.9× Sana Biotechnology Inc's market cap, and Comfort Systems USA Inc pays a 0.15% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

FIXSANA
Market Cap
$61.14B$987.94M
Sector
TechnologyHealth
52-Week High
$2.07K$5.92
52-Week Low
$532.14$2.68
Enterprise Value
$60.42B$962.13M
Dividend Yield
0.15%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Comfort Systems USA Inc

Comfort Systems USA (FIX) trades at $1,655.80, down 6.72% over the past day, amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $10.51 versus $6.81 expected, and revenue growth projected from $9.10B in 2025 to $10.10B in 2026. Analyst consensus remains bullish with a $2,100 price target, supported by robust cash flow and a 53.29% ROE.

Outlook is positive due to AI infrastructure demand and record backlog, though high valuation multiples (P/E 50.14) and execution risks from rapid growth pose challenges. The stock offers growth potential but requires monitoring of margin sustainability and competitive pressures in the contracting services sector.

Sana Biotechnology Inc

Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.

The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Comfort Systems USA Inc

Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.

Read more on FIX

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA